Navigation Links
Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL

Norwood, MA (PRWEB) February 01, 2013

On February 6 at 7:45am, BioPharm Clinical™ will present an educational session on improving study feasibility and investigator selection by using patient pool demographic data at CHI’s Summit for Clinical Operations (SCOPE) in Miami, FL. BioPharm Clinical is also co-sponsoring the summit. Topics to be covered in the presentation include the growing importance of international investigators and how to more closely examine U.S. investigators as they become increasingly active in multiple studies that strain their available patients and resources.

Data analytics in BioPharm Clinical and surveys conducted by the company show…

  • The percent of started studies with U.S. sites only has decreased from 54% to 29% since 2000
  • 53% of investigators are located outside of the U.S.
  • Clinical operations professionals surveyed on investigator selection report that their primary concerns are commitment/availability (56%) and patient pool size (41%), far outweighing every other factor offered in the survey
  • 40% of all U.S. investigators who started a new study in the past three years started more than one
  • The average number of active studies per U.S. investigator has increased approximately 50% (from 1.43 to 2.13) since 2000

“These trends demonstrate how critical it is for clinical operations teams to receive the tools and support they need in order to reliably assess study feasibility and to select investigators who will meet enrollment goals,” said session presenter Sean Melville, Business Development Director of BioPharm Clinical. “At SCOPE, we will show how leading global pharmaceutical companies and clinical research organizations (CROs) are leveraging new streams of data including patient pool demographics – such as those available in our +Precision™ database - to make more informed and efficient trial planning decisions.”

In addition to the presentation and co-sponsoring the summit, BioPharm Clinical will partner with Praxis to welcome attendees to a pre-conference reception at Chophouse Miami on February 4 from 6:00-9:00pm. RSVP for the annual networking event and receive a chance to win an iPad Mini.

To view the summit’s full agenda and register to attend, visit

About BioPharm Clinical
BioPharm Clinical is an exclusive support solution for clinical operations professions, providing real-time trial analytics and the most comprehensive database of sites and investigators. Clients benefit from proprietary calculations tailored to their particular trial requirements, detailed milestone timelines and more as they make critical study feasibility assessments and evaluate investigators for their global programs. Learn more at

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
2. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
3. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
4. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
5. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
6. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
7. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
8. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
9. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. John A. Orwin Joins Array BioPharma Board Of Directors
Post Your Comments:
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... ... 2015 , ... The United States Golf Association (USGA) today announced Dr. Bruce ... Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):